Opening Date: 26 October 2023 Deadline Date: 11 April 2024, 17:00 Brussels time
Expected Outcome: The call targets advancements in regenerative medicine through bio-printing technologies, aiming to achieve the following:
· Enable biomedical scientists to access complete bio-printing units for human tissue regeneration.
· Facilitate the availability of large-scale bio-printed tissues for biomedical research for both industry and academia.
· Inform healthcare professionals on the safe and effective use of advanced therapies.
· Provide healthcare providers with tools for treating conditions with unmet medical needs.
· Offer individual patients personalized medical solutions through bio-printed regenerative medicine.
Tackling diseases and reducing disease burden:
Unlocking the full potential of new tools, technologies and digital solutions for a healthy society:
Maintaining an innovative, sustainable and globally competitive health industry:
Scope: Regenerative medicine stands at the forefront of transforming healthcare by replacing or regenerating human cells, tissues, or organs to restore normal function. Despite the promise of 3D bio-printing with living cells for tissue engineering and drug testing, challenges remain in developing tissue-specific functional 3D bio-printed constructs for transplantation and regenerative medicine, including "in-situ" and 4D bio-printing.
Research Areas: Proposals should form multidisciplinary teams and address:
· Designing effective bio-printing strategies for specific tissues or organs.
· Developing or improving bio-printing equipment for higher resolution and quicker production using diverse biomaterials and cell types.
· Covering the entire bio-printing process, from cell collection to construct delivery, with a focus on scaling up to GMP-conform manufacturing.
· Combining bio-printing technologies for creating fully functional synthetic constructs.
· Engaging with regulatory authorities to ensure compliance and document regulatory knowledge.
Medical Focus and Justification: Projects must justify the chosen medical area (tissue, organ, condition) and consider sex differences at the cellular level. Preclinical and early clinical development stages are eligible, with an emphasis on involving SMEs.
Clinical Studies: Applicants planning to include clinical studies must detail their protocols using the provided template in the submission system.
This funding opportunity aims to overcome the existing barriers in 3D bio-printing, facilitating the large-scale deployment of bio-printed tissues and organs. It encourages innovation in regenerative medicine, supporting the development of groundbreaking treatments for various conditions and advancing healthcare solutions.